[ CAS No. 6294-70-8 ] {[proInfo.proName]}

Name: 6294-70-8|5,6-Dimethylpyrazin-2-amine|97%
Brand: Ambeed
SKU: A218090
Price: 19.0 USD
Availability: InStock
Rating: 90 (29 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 6294-70-8

Structure of 6294-70-8 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 6294-70-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 6294-70-8 ]

SDS Specification

Alternatived Products of [ 6294-70-8 ]

Product Details of [ 6294-70-8 ]

CAS No. :	6294-70-8	MDL No. :	MFCD09835026
Formula :	C₆H₉N₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	JTPCVJQUFYRJES-UHFFFAOYSA-N
M.W :	123.16	Pubchem ID :	222763
Synonyms :

Calculated chemistry of [ 6294-70-8 ]

Physicochemical Properties

Num. heavy atoms :	9
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.33
Num. rotatable bonds :	0
Num. H-bond acceptors :	2.0
Num. H-bond donors :	1.0
Molar Refractivity :	36.37
TPSA :	51.8 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.88 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.16
Log Po/w (XLOGP3) :	0.24
Log Po/w (WLOGP) :	0.68
Log Po/w (MLOGP) :	-0.34
Log Po/w (SILICOS-IT) :	1.06
Consensus Log Po/w :	0.56

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.25
Solubility :	6.96 mg/ml ; 0.0565 mol/l
Class :	Very soluble
Log S (Ali) :	-0.89
Solubility :	15.9 mg/ml ; 0.129 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.02
Solubility :	1.17 mg/ml ; 0.00951 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.84

Safety of [ 6294-70-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 6294-70-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 6294-70-8 ]
Downstream synthetic route of [ 6294-70-8 ]

[ 6294-70-8 ] Synthesis Path-Upstream 1~4

1
[ 69816-37-1 ]
[ 431-03-8 ]
[ 6294-70-8 ]

Yield	Reaction Conditions	Operation in experiment
17%	With sodium hydroxide; sodium acetate In methanol; water	Step 1: 2-Amino-5,6-dimethylpyrazine. Glycine amidine dihydrobromide (620 mg, 2.64 mmol) was stirred in 6 mL of MeOH at -30° C (acetonitrile/CO₂ bath) in a capped flask. Butanedione (232 μL, 2.64 mmol) was stirred separately in 6 mL H₂O with sodium acetate (700 mg) until homogeneous. The diketone was added to the amidine solution by pipet followed by 2.5 mL of 3.6 M NaOH. The yellow solution was allowed to warm slowly to RT and was then stirred overnight. MeOH was removed by rotovap and the aqueous solution extracted 3*30 mL with EtOAc. The combined organic extracts were dried (MgSO₄), filtered and concentrated to a yellow solid which contained some impurities. The solid was triturated with EtOAc/Et₂O and filtered to give pure compound (55 mg, 17percent). ¹H-NMR (400 MHz, CDCl₃) δ7.76 (s, 1H), 4.25 (br s, 2H), 2.40 (s, 3H), 2.37 (s, 3H)
410 mg	With sodium acetate; sodium hydride In methanol; water at 0℃; for 0.5 h;	An aqueous solution (40.0 mL) of 2,3-butanedione (1.55 g) and sodium acetate (4.72 g) was added to a methanol solution (40.0 mL) of 2-aminoacetamidine dihydrobromide (4.24 g) at - 30°C over 10 min. Furthermore, 3.6 mol/L aqueous sodium hydroxide solution (17.0 mL) was added, and the reaction mixture was stirred at 0°C for 30 min and at room temperature overnight. Methanol was evaporated under reduced pressure, water was added, and the mixture was extracted 3 times with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and the obtained residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=50/50 - 0/100) to give the title compound (410 mg). MS(ESI)m/z; 124[M+H]⁺

Reference： [1] Patent: US2003/69284, 2003, A1,
[2] Patent: EP3372601, 2018, A1, . Location in patent: Paragraph 0853; 0854

2
[ 6294-71-9 ]
[ 6294-70-8 ]

Reference： [1] Journal of the American Chemical Society, 1945, vol. 67, p. 802,804
[2] Journal of the American Chemical Society, 1948, vol. 70, p. 1257,1259

3
[ 5774-32-3 ]
[ 6294-70-8 ]

Reference： [1] Journal of the American Chemical Society, 1945, vol. 67, p. 802,804

4
[ 6294-70-8 ]
[ 39213-71-3 ]

Reference： [1] Journal of the American Chemical Society, 1948, vol. 70, p. 1257,1259

[ 6294-70-8 ] Synthesis Path-Downstream 1~31

1
[ 6294-70-8 ]
[ 121347-21-5 ]
4-hydroxy-benzenesulfonic acid-(5,6-dimethyl-pyrazin-2-ylamide) [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1951,vol. 73,p. 2558,2560

2
[ 6294-70-8 ]
[ 121-60-8 ]
N-acetyl-sulfanilic acid-(5,6-dimethyl-pyrazin-2-ylamide) [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1945,vol. 67,p. 802,804

3
[ 6294-70-8 ]
[ 6294-69-5 ]

Yield	Reaction Conditions	Operation in experiment
619 mg	With N-Bromosuccinimide; In acetonitrile; at 0 - 20℃; for 0.5h;	To an acetonitrile solution (8.00 mL) of the compound (519 mg) obtained in Reference Example 433 was added N-bromosuccinimide (749 mg) at 0C, and the reaction mixture was stirred at room temperature for 30 min. Aqueous sodium thiosulfate solution was added and the mixture was extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated, and the obtained residue was purified by silica gel column chromatography (solvent; hexane/ethyl acetate=100/0 - 60/40) to give the title compound (619 mg). MS(ESI)m/z; 202,204[M+H]+

Reference： [1]Journal of the American Chemical Society,1948,vol. 70,p. 1257,1259
[2]Patent: EP3372601,2018,A1 .Location in patent: Paragraph 0861; 0862

4
[ 6294-71-9 ]
[ 6294-70-8 ]

Reference： [1]Journal of the American Chemical Society,1945,vol. 67,p. 802,804
[2]Journal of the American Chemical Society,1948,vol. 70,p. 1257,1259

5
[ 6294-70-8 ]
[ 70-23-5 ]
ethyl 5,6-dimethylimidazo<1,2-a>pyrazine-2-carboxylate [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 195 - 203

6
[ 6294-70-8 ]
[ 638-07-3 ]
ethyl 5,6-dimethylimidazo<1,2-a>pyrazine-2-acetate [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 195 - 203

7
[ 6294-70-8 ]
[ 609-15-4 ]
ethyl 2,5,6-trimethylimidazo<1,2-a>pyrazine-3-carboxylate [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 195 - 203

9
[ 6294-70-8 ]
5,6-dimethylimidazo[1,2-a]pyrazine-2-carboxylic acid [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 195 - 203

10
[ 6294-70-8 ]
5,6-dimethylimidazo[1,2-a]pyrazine-2-acetic acid [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 195 - 203

11
[ 6294-70-8 ]
2,5,6-trimethylimidazo[1,2-a]pyrazine-3-carboxylic acid [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,1997,vol. 32,p. 195 - 203

12
[ 6294-70-8 ]
[ 53114-83-3 ]